Teleradiology Solutions offers pharmaceutical vendors, clinical research organisations and biotechnology organisations the opportunity to shorten their development cycles by using its clinical trials radiology reporting service, a company press release said.
Teleradiology Solutions MD and Chief Radiologist Dr Arjun Kalyanpur said delays in the drug development cycle can be an issue of concern for pharmaceutical and biotechnology firms involved in drug development and R&D. These are related in part to delays in reporting of radiologic scans performed to confirm that the patient has responded positively to the drug being evaluated in the clinical trial, he said.
"The delays are in turn related to the worldwide shortage of radiologists, estimated to be as high as 20 per cent in some studies. We are happy to partner with Biocon and offer our services to ensure timely execution and quality evaluation for clinical trials in radiology," he said.
The organisation offers reporting by radiologists experienced in RECIST (Response Evaluation Criteria In Solid Tumors) and WHO (World Health Organisation) measurement criteria, he said.
According to Biocon Ltd Chairman & Managing Director Kiran Mazumdar-Shaw, "To achieve our main objective, accelerating clinical research, we leverage on an adept mix of technology, experience and personal traits. Keeping in line with our mission, Teleradiology Solutions, given their impressive track record, was the partner of choice to meet our complex image analysis requirements."